<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="417">
  <stage>Registered</stage>
  <submitdate>6/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000377639</actrnumber>
  <trial_identification>
    <studytitle>A randomised phase II study comparing capecitabine with capecitabine and  oral cyclophosphamide in patients with advanced breast cancer</studytitle>
    <scientifictitle>A randomised phase II study comparing the safety and efficacy of capecitabine with capecitabine and  oral cyclophosphamide in patients with advanced breast cancer</scientifictitle>
    <utrn />
    <trialacronym>Cyclox II</trialacronym>
    <secondaryid>Cancer Trials New Zealand: CTNZ 01_03</secondaryid>
    <secondaryid>International Standard Randomized Controlled Trial Number (ISRCTN): ISRCTN68662102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Capecitabine days 1-28 of 28 day cycle vs capecitabine days 1-28 plus oral cyclophosphamide days 1-14 of 28 day cycle.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Toxicity assessed thoughout treatment</outcome>
      <timepoint>Assessed 8 weekly during the treatment period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Best tumour response</outcome>
      <timepoint>Assessed 8 weekly during the treatment period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Survival measures</outcome>
      <timepoint>Assessed at completion of the study.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom response</outcome>
      <timepoint>Throughout treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histological or cytological evidence of breast carcinoma with at least one of the following: distant metasteses, T4 or N2 or N3, or loacal recurrence following mastectomy;measurable disease; treatment with palliative intent; performace status 0-3 (WHO); aequate bone marrow, renal and liver fnction and creatinine clearance &gt; 50ml/min.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Male; less thank six months since last dose of adjuvant chemotherapy; more than one prior regimen for advanced disease; pregnant or breast feeding; concurrent anticancer therapy; other malignancy within 5 years except adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of teh cervix.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Web based randomisation system</concealment>
    <sequence>Web based randomisation system</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>30/03/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Cancer Trials New Zealand</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche International &amp; Roche Products (New Zealand) Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>-</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Vernon Harvey</name>
      <address>Department of Oncology
Auckland Hospital
Park Road
Grafton</address>
      <phone>+64 9 3074949 (Ext. 6265)</phone>
      <fax>+64 9 3072841</fax>
      <email>VernonH@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Michael Findlay</name>
      <address>Cancer Trials New Zealand
Discipline of Oncology
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737927</fax>
      <email>mp.findlay@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>